Key stats
About Tema Oncology ETF
Home page
Inception date
Aug 15, 2023
Structure
Open-Ended Fund
Distributes
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Tax on distributions
Qualified dividends
Primary advisor
Tema Global Ltd.
Distributor
Foreside Fund Services LLC
CANC aims for long-term growth by investing in companies that derive most of their revenue from the field of oncology. This includes large pharmaceutical firms, medical device companies and healthcare service providers whose primary focus is cancer treatment and management. The fund adopts a comprehensive analysis approach, utilizing internal research, external sources, and thematic investing strategies to identify promising investment opportunities within the oncology sector. The portfolio typically consists of 15 to 100 companies that meet minimum market capitalization and trading liquidity requirements. While CANC may hold stocks of companies globally, a substantial portion of its assets are anticipated to be allocated in the US and Europe. Additionally, ESG factors are incorporated in the funds investment process for smart risk management and return optimization. Being actively managed, the portfolio manager has full discretion to make buy, sell, and hold decisions.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.44%
Health Technology97.40%
Health Services1.06%
Technology Services0.98%
Bonds, Cash & Other0.56%
Mutual fund0.53%
Cash0.02%
Stock breakdown by region
North America85.48%
Europe8.86%
Asia5.66%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history